Ambroxol
Ambroxol is a mucolytic medicine used in many countries to help clear thick bronchial secretions. It is nationally authorised rather than centrally authorised across much of Europe, so indications, age limits, strengths and legal status differ by market.
At a glance
Quick facts
- Drug class
- Mucolytic / expectorant
- Main uses
- Symptomatic treatment of respiratory conditions with thick mucus in countries where ambroxol is authorised
- Route
- Oral; inhaled and other formulations exist in some markets
- WHO ATC
- R05CB06
- Key safety
- Hypersensitivity and severe cutaneous adverse reactions are rare but important; treatment should stop and medical advice be sought if a progressive skin or mucosal reaction develops.
- Monitoring
- Symptom course, hydration, underlying respiratory diagnosis, allergy history and age/formulation restrictions.
Names & terminology
How this medicine may be named or searched
- Canonical page name
- Ambroxol
- INN / generic name
- Ambroxol
- Aliases / salts
- ambroxol · ambroxol hydrochloride
- Russian support entity
- ambroksol.ru — entity relationship only, not a clinical source
Structured drug profile
Drug profile
What is Ambroxol?
Ambroxol is a mucolytic medicine used in many countries to help clear thick bronchial secretions. It is nationally authorised rather than centrally authorised across much of Europe, so indications, age limits, strengths and legal status differ by market.
What is Ambroxol used for?
Symptomatic treatment of respiratory conditions with thick mucus in countries where ambroxol is authorised. The exact approved indication depends on the product, route and country. [1]
How it works
Promotes mucus clearance by altering mucus properties and supporting mucociliary activity; approved claims vary between national product labels.
Forms and formulations
Tablets, capsules, syrups, oral solutions and other market-specific formulations. Different formulations may have different indications, strengths, excipients and instructions and should not be assumed interchangeable.
Country / market layer
Availability and formulations by market
Brand names, strengths, prescription status and approved uses vary by jurisdiction. Check the exact national product record before relying on a formulation.
Availability depends on the active ingredient, route and formulation; not every medicine in this reference has a current UK product.
U.S. authorization and formulation availability may differ substantially from Europe and other markets.
How it is used
Use the dose and duration on the local product information. Mucolytics are not a substitute for assessment of persistent breathlessness, high fever, blood in sputum, chest pain or a cough that is worsening rather than resolving.
For prescription treatment, use the patient-specific regimen rather than copying a dose from another person or another formulation.
Side effects
Gastrointestinal upset, taste disturbance and hypersensitivity can occur. European regulators require warnings about severe allergic reactions and severe skin reactions, although these events are uncommon.
Important warnings and monitoring
Stop treatment and seek urgent medical assessment for swelling, breathing difficulty, widespread blistering rash or sores involving the mouth, eyes or genitals. Persistent or severe respiratory symptoms need diagnostic assessment rather than repeated self-treatment.
Monitoring context: Symptom course, hydration, underlying respiratory diagnosis, allergy history and age/formulation restrictions.
Interactions
Clinically important interactions depend on the exact formulation and co-medications. Combination cough-and-cold products may duplicate active ingredients, so check the full label.
Pregnancy and breastfeeding
Pregnancy and breastfeeding recommendations vary by national product. Use only after checking the exact local product information and discussing expected benefit and uncertainty with a clinician or pharmacist.
Overdose and accidental extra doses
Excess ingestion may increase gastrointestinal and other adverse effects. Contact a poison centre or emergency service if a significant overdose is suspected, especially in a child.
Practical clinical context
The most important distinction is between the medicine entity and a specific marketed product. Strength, salt, route, modified-release design, age authorization and prescription status can change between products. When safety or dosing decisions matter, use the exact package leaflet, prescribing information or national regulator record for the product actually being used.
This page deliberately separates general evidence from the project’s Russian-language support site ambroksol.ru; that site identifies the cross-language entity but is not treated as an authority for clinical claims.
Common questions
Frequently asked questions
It is used in some countries as a mucolytic/expectorant for respiratory illnesses with thick mucus; approved indications vary by market.
No. It is a mucus-modifying medicine and does not treat bacterial infection by itself.
European regulators added safety information about rare severe allergic and cutaneous reactions.
No. Availability, age limits and approved uses vary substantially by country.
No. Cough has many causes; persistent, severe or alarming symptoms need assessment rather than automatic mucolytic treatment.
Sources
Clinical statements in this reference are based on named public-health, regulatory or guideline sources. Product-specific labeling remains authoritative for exact indications, dosing and contraindications.
- 1. EMA. Ambroxol and bromhexine-containing medicines referral. Source ↗
- 2. WHO ATC/DDD. ATC/DDD Index. Source ↗
This medicine reference is evidence-based and is awaiting clinician review. It is not a substitute for personalized medical advice.